Leucomethylene blue mesylate_product_DataBase

Bioactivity	Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (Ki of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes[1][2][3].
Target	Ki: 0.12 μM (tau).
Invitro	Leucomethylene blue (100 nM, 48 h) mesylate not only decreases the tau and p-tau expression levels, but also reversed the promoting effects of Aβ25-35 on orexin A and adenosine A1R expression levels[2]. Western Blot Analysis[2] Cell Line:
Name	Leucomethylene blue mesylate
CAS	1236208-20-0
Formula	C18H27N3O6S3
Molar Mass	477.62
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Reference	[1]. Gaudette NF, et al. Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine andB6C3F1 mouse urine. J Anal Toxicol. 2005 Jan-Feb;29(1):28-33. [2]. Zhenhua Liu, et al. Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor. Int J Mol Med. 2019 Jan;43(1):435-442. [3]. Francesco Panza, et al. Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy? Expert Opin Pharmacother. 2016;17(4):457-61.

PeptideDB